Shares of Delcath Systems Inc. (DCTH) touched a new 52-week high of $16.97 last week, and that reflects a gain of over 100% in less than 6 months.
This interventional oncology company, focused on the treatment of primary and metastatic cancers of the liver, markets HEPZATO KIT, a drug/device combination product, which is comprised of the chemotherapeutic drug Melphalan and Delcath's proprietary Hepatic Delivery System (HDS).
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.